Einzeltreffer — DigiBib

HCV infection has been hypothesized as a contributor of poor CD4 + recovery in patients living with HIV (PLWHIV). Aim of this study was to evaluate CD4 + , CD8 + cells and CD4/CD8 ratio trends before and after HCV treatment with direct acting agents (DAA) in PLWHIV. HIV/HCV patients enrolled in ICONA and HepaICONA cohorts with HIV-RNA≤50 copies/ml who achieved a sustained viral response after DAA treatment were studied. A linear regression model was used to investigate CD4 + , CD8 + and CD4/CD8 changes 12 months before and after DAA treatment. A total of 939 HIV/HCV patients were included, 225 (24.0%) female, median age: 53 years (IQR 50-56). At DAA initiation, CD4 + T cell count was <350 cells/mm 3 in 164 patients (17.5%), and 246 patients (26.2%) had liver stiffness>12.5 kPa. Trends of CD4 + and CD4/CD8 ratio were similar before and after DAA in all study populations (CD4 + change +17.6 cells/mm 3 (95%CI -33.5; 69.4, p = 0.494); CD4/CD8 change 0.013 (95%CI -0.061; 0.036, p = 0.611). However, patients treated with ribavirin (RBV)-free DAA showed a significant decrease in CD8 + cells (-204.3 cells/mm 3 , 95%CI -375.0;-33.4, p = 0.019), while patients treated with RBV experienced CD8 + cell increase (+141.2 cells/mm 3 , 95%CI 40.3; 242.1, p = 0.006). In conclusion, HCV eradication following DAA treatment does not seem to have an impact on CD4 + T cell recovery in PLWHIV. However, a fast decline of CD8 + T cells has been observed in patients treated without RBV, suggesting a favourable effect of HCV clearance on the general state of immune activation.

Titel:	The impact of DAA-mediated HCV eradication on CD4 <superscript>+</superscript> and CD8 <superscript>+</superscript> T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort.
Autor/in / Beteiligte Person:	Bandera, A ; Lorenzini, P ; Taramasso, L ; Cozzi-Lepri, A ; Lapadula, G ; Mussini, C ; Saracino, A ; Ceccherini-Silberstein, F ; Puoti, M ; Quiros-Roldan, E ; Montagnani, F ; Antinori, A ; d'Arminio Monforte A ; Gori, A
Link:	Volltext (PDF)
Zeitschrift:	Journal of viral hepatitis, Jg. 28 (2021-05-01), Heft 5, S. 779-786
Veröffentlichung:	Oxford ; Boston : Blackwell Scientific Publications, 1994-, 2021
Medientyp:	academicJournal
ISSN:	1365-2893 (electronic)
DOI:	10.1111/jvh.13488
Schlagwort:	Antiviral Agents therapeutic use CD4 Lymphocyte Count CD4-Positive T-Lymphocytes CD8-Positive T-Lymphocytes Female Hepacivirus genetics Humans Middle Aged Coinfection drug therapy HIV Infections complications HIV Infections drug therapy Hepatitis C drug therapy
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Corporate Authors: Icona Foundation Cohort Publication Type: Journal Article Language: English [J Viral Hepat] 2021 May; Vol. 28 (5), pp. 779-786. <i>Date of Electronic Publication: </i>2021 Mar 11. MeSH Terms: Coinfection* / drug therapy ; HIV Infections* / complications ; HIV Infections* / drug therapy ; Hepatitis C* / drug therapy ; Antiviral Agents / therapeutic use ; CD4 Lymphocyte Count ; CD4-Positive T-Lymphocytes ; CD8-Positive T-Lymphocytes ; Female ; Hepacivirus / genetics ; Humans ; Middle Aged References: Boulougoura A, Sereti I. HIV infection and immune activation: the role of coinfections. Curr Opin HIV AIDS. 2016;11(2):191-200. ; Hodowanec AC, Lee RD, Brady KE, et al. A matched cross-sectional study of the association between circulating tissue factor activity, immune activation and advanced liver fibrosis in hepatitis C infection. BMC Infect Dis. 2015;15:190. ; Márquez M, Romero-Cores P, Montes-Oca M, et al. Immune activation response in chronic HIV-infected patients: influence of Hepatitis C virus coinfection. PLoS One. 2015;10(3):e0119568. ; Gonzalez VD, Falconer K, Blom KG, et al. High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment. J Virol. 2009;83(21):11407-11411. ; Sajadi MM, Pulijala R, Redfield RR, Talwani R. Chronic immune activation and decreased CD4 cell counts associated with hepatitis C infection in HIV-1 natural viral suppressors. AIDS. 2012;26(15):1879-1884. ; Hodowanec AC, Brady KE, Gao W, et al. Characterization of CD4+ T-cell immune activation and interleukin 10 levels among HIV, hepatitis C virus, and HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr. 2013;64(3):232-240. ; Paiardini M, Müller-Trutwin M. HIV-associated chronic immune activation. Immunol Rev. 2013;254(1):78-101. ; Gazzola L, Tincati C, Bellistrì GM, d’Arminio MA, Marchetti G. The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin Infect Dis. 2009;48(3):328-337. ; Kushner LE, Wendelboe AM, Lazzeroni LC, et al. Immune biomarker differences and changes comparing HCV mono-infected, HIV/HCV co-infected, and HCV spontaneously cleared patients. PLoS One. 2013;8(4):e60387. ; Chew KW, Hua L, Bhattacharya D, et al. The effect of hepatitis C virologic clearance on cardiovascular disease biomarkers in human immunodeficiency virus/hepatitis C virus coinfection. Open Forum Infect Dis. 2014;1(3):ofu104. ; López-Cortés LF, Trujillo-Rodríguez M, Báez-Palomo A, et al. Eradication of Hepatitis C Virus (HCV) Reduces Immune Activation, Microbial Translocation, and the HIV DNA Level in HIV/HCV-Coinfected Patients. J Infect Dis. 2018;218(4):624-632. ; Emmanuel B, El-Kamary SS, Magder LS, et al. Immunological recovery in T-cell activation after sustained virologic response among HIV positive and HIV negative chronic Hepatitis C patients. Hepatol Int. 2019;13(3):270-276. ; Shmagel KV, Korolevskaya LB, Saidakova EV, et al. HCV coinfection of the HIV-infected patients with discordant CD4+ T-cell response to antiretroviral therapy leads to intense systemic inflammation. Dokl Biol Sci. 2017;477(1):244-247. ; Maria AD, Cossarizza A. CD4saurus Rex & HIVelociraptor vs. development of clinically useful immunological markers: a Jurassic tale of frozen evolution. J Transl Med. 2011;9:93. ; Meissner EG, Kohli A, Higgins J, et al. Rapid changes in peripheral lymphocyte concentrations during interferon-free treatment of chronic hepatitis C virus infection. Hepatol Commun. 2017;1(7):586-594. ; Orr C, Aartun J, Masur H, Kottilil S, Meissner EG. Characterization of changes in intrahepatic immune cell populations during HCV treatment with sofosbuvir and ribavirin. J Viral Hepat. 2019;26(3):323-328. ; Tam RC, Pai B, Bard J, et al. Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile. J Hepatol. 1999;30(3):376-382. ; Powers CN, Peavy DL, Knight V. Selective inhibition of functional lymphocyte subpopulations by ribavirin. Antimicrob Agents Chemother. 1982;22(1):108-114. ; EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol. 2017;66(1):153-194. ; Martín J, Navas S, Quiroga JA, Pardo M, Carreño V. Effects of the ribavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients. Cytokine. 1998;10(8):635-644. Contributed Indexing: Investigator: M Andreoni; A Castagna; F Castelli; R Cauda; G Di Perri; M Galli; R Iardino; G Ippolito; A Lazzarin; GC Marchetti; G Rezza; F von Shloesser; P Viale; A Castagna; E Girardi; S Lo Caputo; F Maggiolo; CF Perno; F Bai; S Bonora; M Borderi; A Calcagno; MR Capobianchi; A Castagna; S Cicalini; A Cingolani; P Cinque; A Di Biagio; R Gagliardini; E Girardi; N Gianotti; G Guaraldi; M Lichtner; A Lai; G Madeddu; F Maggiolo; G Marchetti; E Merlini; S Nozza; CF Perno; S Piconi; C Pinnetti; R Rossotti; S Rusconi; MM Santoro; L Sarmati; V Spagnuolo; V Svicher; I Fanti; L Galli; A Rodano'; M Macchia; A Tavelli; A Bove; A Camposeragna; M Errico; M Manfredini; A Perziano; V Calvino; F Carletti; S Carrara; A Di Caro; S Graziano; F Petroni; G Prota; S Truffa; A Giacometti; A Costantini; V Barocci; G Angarano; L Monno; E Milano; F Maggiolo; C Suardi; P Viale; V Donati; G Verucchi; F Castelnuovo; C Minardi; B Menzaghi; C Abeli; L Chessa; F Pes; B Cacopardo; B Celesia; J Vecchiet; K Falasca; A Pan; S Lorenzotti; L Sighinolfi; D Segala; P Blanc; F Vichi; G Cassola; M Bassetti; A Alessandrini; N Bobbio; G Mazzarello; M Lichtner; L Fondaco; P Bonfanti; C Molteni; A Chiodera; P Milini; G Nunnari; G Pellicanò; M Galli; A Lazzarin; G Rizzardini; A Castagna; ES Cannizzo; MC Moioli; R Piolini; D Bernacchia; A Poli; C Tincati; C Puzzolante; C Migliorino; V Sangiovanni; G Borgia; V Esposito; G Di Flumeri; I Gentile; V Rizzo; AM Cattelan; S Marinello; A Cascio; M Trizzino; D Francisci; E Schiaroli; G Parruti; F Sozio; C Lazzaretti; R Corsini; M Andreoni; R Cauda; A Cristaudo; V Vullo; R Acinapura; S Lamonica; M Capozzi; A Mondi; A Cingolani; M Rivano Capparuccia; G Iaiani; A Latini; G Onnelli; MM Plazzi; G De Girolamo; A Vergori; M Cecchetto; F Viviani; G Madeddu; A De Vito; B Rossetti; A Franco; R Fontana Del Vecchio; C Di Giuli; P Caramello; G Di Perri; S Bonora; GC Orofino; M Sciandra; A Londero; V Manfrin; G Battagin; G Starnini; A Ialungo ; Keywords: CD4; CD8; DAA; HCV/HIV; immune activation Substance Nomenclature: 0 (Antiviral Agents) Entry Date(s): Date Created: 20210218 Date Completed: 20211001 Latest Revision: 20211001 Update Code: 20240513

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

The impact of DAA-mediated HCV eradication on CD4 <superscript>+</superscript> and CD8 <superscript>+</superscript> T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort.